SUMMARY

As the COVID-19 pandemic is a challenge for all of us, the EHA meeting was the occasion to exchange experiences about initiatives developed with the aim of improving the management of patients suffering from a pathology of the red blood cell and infected with COVID-19. It was also an opportunity to present the developments observed in clinical studies involving new therapies or the combination of therapies, or to get an overview of the evolutions in the field of red blood cell diseases.

(BELG J HEMATOL 2020;11(5):226-9)